Taxane chemotherapy and new microtubule-interactive agents

Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs

Volumn 2, Issue 3, 2000, Pages 305-311

  Morsman, J M ^a   McLeod, H L ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Microtubules; Oral chemotherapy; Paclitaxel; Pharmacodynamics; Resistance; Tubulin

Indexed keywords

14 BETA HYDROXY 10 DEACETYLBACCATIN III; ACTINOMYCIN DERIVATIVE; ANTIMITOTIC AGENT; BACCATIN III; BENZENE DERIVATIVE; BETA TUBULIN; COLCHICINE; CYCLOSPORIN; DISCODERMOLIDE; DOCETAXEL; DOXORUBICIN; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; GLYCOPROTEIN P; MICROTUBULE ASSOCIATED PROTEIN; ORTATAXEL; PACLITAXEL; T 138067; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE MUTATION; HUMAN; MICROTUBULE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 0033856554     PISSN: 14648466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
2. Tubulin and microtubute structure
3. Multiple forms of tubulin: Different gene products and covalent modifications
4. Microtubules and actin filaments: Dynamic targets for caner chemotherapy
5. Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome
6. Dynamic instability of microtubule growth
7. Microtubule treadmilling in vivo
8. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
9. Vinblastine suppresses dynamics of individual microtubules in living interphase cells
10. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
11. Taxol-Induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
12. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
13. Bcl2 is the guardian of microtubule integrity
14. Bcl-xL is phosphorylated in malignant cells following microtubule disruption
15. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis
16. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents
17. Tubulin/microtubules: Still a promising target for new chemotherapeutic agents
18. Promotion of microtubule assembly in vitro by taxol
19. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition
20. Solution structure of taxotere-induced microtubules to 3-nm resolution
21. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
22. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
23. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance
24. A common pharmacophore for epothiloneand taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
25. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
26. Taxol: Pharmacology, metabolism and clinical implications
27. The taxanes: An update
28. Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors
29. Cytostatic and apoptotic effects of paclitaxel in human breast tumors
30. Pharmacologic effects of paclitaxel in human bladder tumors
31. Pharmacodynamics of taxol in human head and neck tumors
32. Differential time dependency of antiproliferative and apoptotic effects of Taxol in human prostate tumors
33. Relationship between paclitaxel activity and pathobiology of human solid tumors
34. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention
35. Determinants of paclitaxel penetration and accumulation in human solid tumour
36. Oral chemotherapy: Rationale and future directions
37. Oral cancer chemotherapy: The promise and the pitfalls
38. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) cuased by P-glycoprotein in the intestine
39. Co-administration of cyclosporin enables oral therapy with paclitaxel
40. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
41. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
42. IDN5109, a taxane with oral bioavailability and potent antitumor activity
43. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts
44. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanisms of action
45. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®)
46. Synthesis of epothilones A and B in solid and solution phase
47. (+)-discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest
48. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
49. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells
50. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol®)
51. The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site
52. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors